Investigative Gene Therapy for Fanconi Anemia Receives PRIME Designation
A Fanconi Anemia (FA) investigative gene therapy now has PRIority MEdicines (PRIME) designation from the EMA. This designation helps to accelerate the development of therapies for patient populations who have…